Login to Your Account

HGSI Shares Get a Bump on BLA Submission in Lupus

By Donna Young

Friday, June 11, 2010
Investors were pleased Thursday with Human Genome Sciences Inc.'s news that it had submitted its much-anticipated biologics license application (BLA) to the FDA for Benlysta (belimumab) as a treatment for systemic lupus erythematosus (SLE), pushing shares of the firm up 8.2 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription